



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/760,115		01/16/2004	John Cambier	2879-101	7382
22442	7590	03/29/2006		EXAM	INER
SHERIDAI 1560 BROA		PC	BELYAVSKYI, MICHAIL A		
SUITE 1200				ART UNIT	PAPER NUMBER
DENVER, CO 80202				1644	
				DATE MAILED: 03/29/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/760,115	CAMBIER ET AL.
Office Action Summary	Examiner	Art Unit
	Michail A. Belyavskyi	1644
The MAILING DATE of this communication Period for Reply	appears on the cover sheet wit	h the correspondence address
A SHORTENED STATUTORY PERIOD FOR RE WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFF after SIX (6) MONTHS from the mailing date of this communication - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by st Any reply received by the Office later than three months after the m earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC R 1.136(a). In no event, however, may a re riod will apply and will expire SIX (6) MONT atute, cause the application to become AB/	CATION. ply be timely filed I'HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
Status		
1)☐ Responsive to communication(s) filed on 2a)☐ This action is FINAL. 2b)☑ 1 3)☐ Since this application is in condition for allo closed in accordance with the practice under the condition is in condition.	This action is non-final. wance except for formal matte	• •
Disposition of Claims		
4) Claim(s) <u>1-41</u> is/are pending in the applicat 4a) Of the above claim(s) is/are with 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-41</u> are subject to restriction and/	drawn from consideration.	
Application Papers		
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the con 11) The oath or declaration is objected to by the	accepted or b) objected to be the drawing(s) be held in abeyand rection is required if the drawing(s	ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International Bur * See the attached detailed Office action for a	ents have been received. ents have been received in Appriority documents have been reau (PCT Rule 17.2(a)).	oplication No received in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/Paper No(s)/Mail Date	Paper No(s)	ummary (PTO-413) /Mail Date formal Patent Application (PTO-152)

Application/Control Number: 10/760,115

Page 2

DETAILED ACTION

1. Claims 1-41 are pending.

Art Unit: 1644

Restriction Requirement

- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claim 2, drawn to the isolated myeloid cell, wherein said cell expresses F4/80, classified in Class 435, subclass 325.
- II. Claim 3, drawn to the isolated myeloid cell, wherein said cell expresses CD68, classified in Class 435, subclass 325.
- III. Claim 4, drawn to the isolated myeloid cell, wherein said cell expresses CCR3, classified in Class 435, subclass 325.
- IV. Claim 5, drawn to the isolated myeloid cell, wherein said cell expresses B220, classified in Class 435, subclass 325.
- V. Claim 6, drawn to the isolated myeloid cell, wherein said cell does not stain with vital red, classified in Class 435, subclass 325.
- VI. Claim 8, drawn to the isolated myeloid cell, wherein said cell does not express TcR, classified in Class 435, subclass 325.
- VII. Claim 9, drawn to the isolated myeloid cell, wherein said cell is a murine cell, classified in Class 435, subclass 354.
- VIII. Claim 10, drawn to the isolated myeloid cell, wherein said cell is a human cell, classified in Class 435, subclass 366.
- IX. Claim 20, drawn to the isolated myeloid cell, wherein said cell is immortalized, classified in Class 435, subclass 366.
- X. Claim 25-26, drawn to vaccine, comprising an isolated myeloid cell and at least one antigen classified in Class 424, subclass 93.1.
- X. Claim 27, drawn to vaccine, comprising an isolated myeloid cell and cytokine classified in Class 424, subclass 93.1.

Application/Control Number: 10/760,115

Art Unit: 1644

XI. Claims 28-34, drawn to a method for enhancing a thymus-dependent immune response classified in Class 424, subclass 578.

- XII. Claims 35 36, 38 and 39 drawn to a method to produce a myeloid cell that mediates thymus-dependent immune responses, classified in Class 435, subclass 372; Class 424, subclass 578.
- XIII. Claims 37, 40and 41 drawn to a method to a method to identify agents that enhance thymus-mediated immune response, classified in Class 435, subclass 372; Class 424, subclass 578.
- 3. Claims 1, 11-19 and 21-24 link inventions of Groups I-X. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 46-50 and 54-58 or 62-66 and 70-74. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.
- 4. Groups I –X are different products. These inventions differ with respect to their structures and physicochemical properties, which require non-coextensive searches; therefore each product is patentably distinct
- 5. Groups XI- XIII are different methods. These inventions are different with respect to ingredients, method steps, and endpoints which require non-coextensive searches; therefore, each method is patentably distinct.
- 6. Groups I-X and XI are related as product and process of using. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the isolated myeloid cell and progenitor cells can be used to produced conditioning media in addition to the recited method.

Page 3

Art Unit: 1644

7. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Moreover, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention. Therefore restriction for examination purposes as indicated is proper.

8. The examiner has required restriction between product and process claims. If applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Art Unit: 1644

- 10. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement may be traversed.
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840 The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/272-0841.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MICHAIL BELYAVSKYI, PH.D. PATENT EXAMINER

3/22/06